Get the Stockscreener App
45.95
4.63%
-2.23
After Hours:
45.95
Crinetics Pharmaceuticals Inc stock is traded at $45.95, with a volume of 3.60M.
It is down -4.63% in the last 24 hours and down -1.54% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$48.18
Open:
$47.4
24h Volume:
3.60M
Relative Volume:
2.65
Market Cap:
$4.36B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-12.32
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-3.04%
1M Performance:
-1.54%
6M Performance:
+54.19%
1Y Performance:
-8.99%
1-Day Range:
$43.40
$48.25
1-Week Range:
$43.40
$57.99
52-Week Range:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
45.95 | 4.57B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00 - MarketBeat
Early PALSONIFY Launch and Atumelnant Data Might Change The Case For Investing In Crinetics (CRNX) - simplywall.st
Crinetics Pharmaceuticals shares down 6.4% after announcing $350 million stock offering - marketscreener.com
Crinetics stock maintains Buy rating at H.C. Wainwright on strong CAH data - Investing.com
Crinetics stock outperforms with strong Palsonify sales, Oppenheimer reiterates $87 target - Investing.com UK
Crinetics Pharma ticks down after announcing $350 mln stock offering - TradingView — Track All Markets
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD - Investing.com
Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares - TipRanks
Crinetics Pharmaceuticals Stock: Biotech Optimism Meets Volatile Reality - AD HOC NEWS
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Crinetics plans $350 mln public share offering - MSN
Crinetics Reports Strong Palsonify Launch To Date, Positive Phase II CAH Data - Citeline News & Insights
Crinetics Pharmaceuticals announces proposed public offering of common stock - marketscreener.com
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Highlights Strong PALSONIFY Launch and Trial Progress - TipRanks
Crinetics Pharmaceuticals Plans $350 Million Public Offering - marketscreener.com
Crinetics Pharmaceuticals plans $350 million stock offering - Investing.com India
Crinetics stock ticks lower after announcing $350 million public offering - Investing.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - The Manila Times
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Drugmaker seeks $350M to launch PALSONIFY and fund new therapies - Stock Titan
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial - MSN
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Stocktwits
Crinetics Pharmaceuticals’ Latest Trial Sparks Market Movement - StocksToTrade
Crinetics stock price target raised to $97 from $85 at Jones Trading - Investing.com
Baird reiterates Outperform rating on Crinetics stock as Palsonify launch exceeds expectations - Investing.com
Crinetics stock price target raised to $80 from $77 at Morgan Stanley - Investing.com UK
Crinetics reports robust full-quarter sales for rare disease drug Palsonify - Endpoints News
Crinetics stock price target raised to $90 from $80 at Evercore ISI - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week HighStill a Buy? - MarketBeat
Crinetics reports Q4 PALSONIFY U.S. preliminary net product revenue of over $5M - TipRanks
Crinetics stock maintains Buy rating at Stifel on positive clinical data - Investing.com Australia
Crinetics (CRNX) Reports Promising Phase II Data for CAH Treatme - GuruFocus
Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data - MarketBeat
Why Is Crinetics Pharma Stock Soaring Monday?Crinetics Pharmaceuticals (NASDAQ:CRNX) - Benzinga
Crinetics Pharmaceuticals stock hits 52-week high at 55.23 USD By Investing.com - Investing.com South Africa
Crinetics stock soars after strong PALSONIFY launch and positive trial data - Investing.com Canada
Crinetics stock soars after strong PALSONIFY launch and positive trial data By Investing.com - Investing.com South Africa
Why Crinetics Pharmaceuticals Stock Is Sliding Now - TipRanks
Crinetics reports over $5 million in Q4 revenue from acromegaly drug - Investing.com India
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia - The Manila Times
Crinetics to host conference call on paltusotine and atumelnant data By Investing.com - Investing.com Nigeria
Crinetics to host conference call on paltusotine and atumelnant data - Investing.com
Crinetics Pharmaceuticals to Host Conference Call on January 5, 2026, for PALSONIFY™ Update and Phase 2 Trial Results of Atumelnant - Quiver Quantitative
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - The Manila Times
Live briefing to share atumelnant results in congenital adrenal hyperplasia - Stock Titan
Avoiding Lag: Real-Time Signals in (CRNX) Movement - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - MSN
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):